Precision Medicine

New data reveals Mesoblast's cell therapy Ryoncil dramatically boosts survival in GvHD patients when used early, paving the way for a major adult trial.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

Hoag becomes the world's first Center of Excellence in Oncoplastic Surgery, a revolutionary approach merging cancer removal with cosmetic preservation.

Facing a national crisis of long waits for autism diagnosis, a new free online tool from Catalight hopes to connect families with care in days, not months.

A 'world-first' cervical implant from Zavation Medical Products combines two materials to enhance bone growth while maintaining critical imaging capabilities.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

A new health tech firm says its unified platform can fix patient confusion and provider burnout. But in a crowded market, can one company truly solve it all?

Global marketing giant Dentsu partners with BranchLab, using AI to target health audiences with unprecedented precision while upholding patient privacy.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

Bio-Techne promotes Steve Crouse to lead its high-growth Diagnostics and Spatial Biology unit, signaling a strategic focus on innovation after a key divestiture.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

Insight Molecular Diagnostics secures $26M to expand its transplant rejection test to the heart market, backed by a major shareholder amid market dilution concerns.

SOFIE Biosciences' FAPI-PRO trial begins, testing a novel radiotracer that could revolutionize the detection of one of the deadliest forms of cancer.

Pharma veteran Pinder Sahota joins digital health firm Reset Health, signaling a strategic shift to integrated care in the new era of weight-loss drugs.

Zelluna partners with Medpace for a first-in-human trial of its ZIMA-101 TCR-NK therapy, a new 'off-the-shelf' approach for hard-to-treat solid tumors.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Bolstered by a top regulatory expert and unique veterinary data, Vivos Inc. is set to file for human trials of its precision injectable cancer treatment.

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.